CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
BAXERNA 2.0 aims to create a new pipeline for developing mRNA vaccines targeting resistant bacterial pathogens, including Mycobacterium tuberculosis and Acinetobacter baumannii. By utilizing advanced immunopeptidomics and innovative vaccine formulations, the project seeks to enhance immune responses and facilitate effe…
BAXERNA 2.0 will establish a new vaccine development pipeline based on dramatically improved immunopeptidomics screening and innovative mRNA vaccine formulation.
We will use our powerful new pipeline to develop novel mRNA vaccines against three bacterial pathogens that can persist within phagocytic cells:
Mycobacterium tuberculosis (MTB), Mycobacterium ulcerans (MU), and Acinetobacter baumannii (AB). MTB and AB are clinically problematic bacteria with alarming levels of antimicrobial resistance…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Belgium, Gent
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Sweden, Stockholm
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, NIJMEGEN
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
